针对儿科急性淋巴细胞白血病的分子向小分子抑制剂疗法:临床试验的全面审查
Nicolò Peccatori1,2,3,4, Erica Brivio4, Andrej Lissat5
1Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori, 20900 Monza, Italy.
Cancers
|October 29, 2025
概括
向疗法和免疫疗法为患有急性淋巴细胞白血病 (ALL) 的儿童提供了新的希望,特别是那些患有复发或高风险疾病的儿童. 这些精准医学方法旨在提高治愈率,同时降低化疗毒性.
科学领域:
- 儿科血液瘤学
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 急性淋巴细胞白血病 (ALL) 治疗的显著进展改善了许多儿童的治疗结果.
- 然而,复发性/耐药性疾病和高风险遗传特征仍然具有挑战性,传统化疗接近其疗效极限.
- 需要创新策略来提高治愈率并最大限度地减少治疗毒性.
研究的目的:
- 审查儿童急性淋巴细胞白血病 (ALL) 的分子向治疗方法.
- 总结已完成的临床试验的发现,并强调正在进行的/即将进行的试验.
- 为未来的方向提供洞察力,以精确优化ALL治疗.
主要方法:
- 对儿科ALL分子向治疗的综合文献综述.
- 从已完成和正在进行的临床试验中分析数据.
- 专注于下一代测序的进展,以实现风险分层和治疗优化.
主要成果:
- 分子向疗法和免疫疗法正在重塑儿童ALL治疗范式.
- 下一代测序方便个性化风险分层和治疗选择.
- 临床试验对于完善复杂的治疗策略和改善治疗结果至关重要.
结论:
- 分子向治疗是儿科ALL精准医学的基石.分子向治疗是儿科ALL精准医学的基石.
- 进一步的研究和临床试验对于优化这些新方法至关重要.
- 精确驱动的策略具有显著的潜力,可以改善儿科B-ALL和T-ALL的结果.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
240
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
240


